Amarin reported $-27527000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
DBV Technologies DBVT:US -13640000 3.49M
Abbvie ABBV:US $ 7127M 482M
Aerie Pharmaceuticals AERI:US $ -32.04M 85.4M
Alnylam Pharmaceuticals ALNY:US $ -137.27M 45.91M
Amarin AMRN:US $ -27.53M 44.04M
AstraZeneca AZN:LN 4187M 687M
Biocryst Pharmaceuticals BCRX:US $ -49.64M 2.37M
Epizyme EPZM:US $ -49.63M 0.33M
Esperion Therapeutics ESPR:US $ -42836000 611K
GlaxoSmithKline GSK:LN 3120M 1062M
Halozyme Therapeutics HALO:US $ 76.45M 19.11M
Heron Therapeutics HRTX:US $ -62.2M 9.46M
Intercept Pharmaceuticals ICPT:US $ -9.9M 10.55M
JAZZ PHA JAZZ:US $ 267.26M 90.66M
Nektar Therapeutics NKTR:US $ -111.36M 1.88M
Neurocrine Biosciences NBIX:US $ 6.4M 60.6M
Novartis NOVN:VX SF 4552M 346M
Teva Pharmaceutical Industries TEVA:US $ 1112M 176M